Nucleus RadioPharma: Clarity and Nucleus RadioPharma scale up manufacturing for cancer treatment

Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company, has entered into a Master Services Agreement (MSA) and Clinical Manufacturing Agreement for the production of 67Cu-SAR-bisPSMA, a radiopharmaceutical treatment for prostate cancer. The post Clarity and Nucleus RadioPharma scale up manufacturing for cancer treatment appeared first on Australian Manufacturing.